Historical Perspective: Models of Parkinson's Disease

被引:216
|
作者
Chia, Shyh Jenn [1 ]
Tan, Eng-King [1 ,2 ,3 ]
Chao, Yin-Xia [1 ,2 ,3 ]
机构
[1] Natl Neurosci Inst, Singapore 308433, Singapore
[2] Singapore Gen Hosp, Dept Neurol, Singapore 169856, Singapore
[3] Duke NUS Med Sch, Singapore 169857, Singapore
基金
英国医学研究理事会;
关键词
Parkinson disease models; neurotoxic models; genetic models; advantages; limitations; ALPHA-SYNUCLEIN; MOUSE MODEL; PRIMATE MODELS; MOTOR DEFICITS; ANIMAL-MODELS; LRRK2; KINASE; MPTP; MUTATIONS; PARAQUAT; ROTENONE;
D O I
10.3390/ijms21072464
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor signs. The current therapeutic regimen for PD is mainly symptomatic as the etio-pathophysiology has not been fully elucidated. A variety of animal models has been generated to study different aspects of the disease for understanding the pathogenesis and therapeutic development. The disease model can be generated through neurotoxin-based or genetic-based approaches in a wide range of animals such as non-human primates (NHP), rodents, zebrafish, Caenorhabditis (C.) elegans, and drosophila. Cellular-based disease model is frequently used because of the ease of manipulation and suitability for large-screen assays. In neurotoxin-induced models, chemicals such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat are used to recapitulate the disease. Genetic manipulation of PD-related genes, such as alpha-Synuclein(SNCA), Leucine-rich repeat kinase 2 (LRRK2), Pten-Induced Kinase 1 (PINK1), Parkin(PRKN), and Protein deglycase (DJ-1) Are used in the transgenic models. An emerging model that combines both genetic- and neurotoxin-based methods has been generated to study the role of the immune system in the pathogenesis of PD. Here, we discuss the advantages and limitations of the different PD models and their utility for different research purposes.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Classic animal models of Parkinson's disease: a historical perspective
    Hamadjida, Adjia
    Frouni, Imane
    Kwan, Cynthia
    Huot, Philippe
    BEHAVIOURAL PHARMACOLOGY, 2019, 30 (04): : 291 - 310
  • [2] Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective
    Rajashree Banerjee
    Arushi Rai
    Shreyas M.Iyer
    Sonia Narwal
    Meghana Tare
    Animal Models and Experimental Medicine, 2022, 5 (01) : 27 - 37
  • [3] Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective
    Banerjee, Rajashree
    Rai, Arushi
    Iyer, Shreyas M.
    Narwal, Sonia
    Tare, Meghana
    ANIMAL MODELS AND EXPERIMENTAL MEDICINE, 2022, 5 (01) : 27 - 37
  • [4] Historical perspective of cell transplantation in Parkinson's disease
    Alejandra Boronat-García
    Magdalena Guerra-Crespo
    René Drucker-Colín
    World Journal of Transplantation, 2017, 7 (03) : 179 - 192
  • [5] Resurgence of functional neurosurgery for Parkinson's disease: A historical perspective
    Speelman, JD
    Bosch, DA
    MOVEMENT DISORDERS, 1998, 13 (03) : 582 - 588
  • [6] Historical perspective: The pros and cons of conventional outcome measures in Parkinson's disease
    Lim, Shen-Yang
    Tan, Ai Huey
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : S47 - S52
  • [7] Models of Parkinson's disease
    Orth, M
    Tabrizi, SJ
    MOVEMENT DISORDERS, 2003, 18 (07) : 729 - 737
  • [8] Models of Parkinson's disease
    Naoi, M
    Maruyama, W
    CATECHOLAMINE RESEARCH: FROM MOLECULAR INSIGHTS TO CLINICAL MEDICINE, 2002, 53 : 479 - 482
  • [9] Rodent models for gait network disorders in Parkinson's disease - a translational perspective
    Wenger, Nikolaus
    Vogt, Arend
    Skrobot, Matej
    Garulli, Elisa L.
    Kabaoglu, Burce
    Salchow-Hoemmen, Christina
    Schauer, Thomas
    Kroneberg, Daniel
    Schuhmann, Michael K.
    Harms, Christoph
    Endres, Matthias
    Isaias, Ioannis U.
    Tovote, Philip
    Blum, Robert
    Ip, Chi Wang
    EXPERIMENTAL NEUROLOGY, 2022, 352
  • [10] Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician's Perspective
    Sturchio, Andrea
    Rocha, Emily M.
    Kauffman, Marcelo A.
    Marsili, Luca
    Mahajan, Abhimanyu
    Saraf, Ameya A.
    Vizcarra, Joaquin A.
    Guo, Ziyuan
    Espay, Alberto J.
    BRAIN SCIENCES, 2024, 14 (02)